Poster numbers poster presentations

Nr. Titel of poster abstract	Presenting author
1 Lamotrigine Use in Lactating Women: Passage into Breast Milk and Infant Exposure	Daphne den Besten-Bertholee
2 Identifying high-risk medication during pregnancy for adverse pregnancy outcomes in Electronic Patient Files (EPF) using disproportional analysis	Dr. Peter Ter Horst
3 Medication screening in pregnant women for cord blood donation in extremely preterm neonates	Robert Flint
4 Spontaneous adverse drug reaction reporting of congenital malformations, a Danish national register study	Dr. Ulrik Lausten-Thomsen
5 Pediatric medication from off-label to on-intelligent-evidence	Anette Kirstine Stark
6 Angiotensin II/angiotensin I ratio as pharmacodynamic parameter in healthy adults and children with heart failure treated with enalapril: insights from an adult population pharmacokinetic-pharmacodynamic model and the LENA studies	Melina Steichert
7 A pharmacovigilance study on the association between proton-pump inhibitors and inappropriate neonatal use based on the FAERS database	Assoc. Prof. Nadir Yalcin
8 AMI FABRY – A Triple Relief for Pain, Gut, and Mood in Fabry Disease using Amitriptylin	Anna-Maria Wiesinger
9 Drug interactions in critically ill neonates undergoing therapeutic hypothermia: a single centre study.	PharmDr. Kateřina Kaňková
10 Leveraging existing evidence on off-label prescribed drugs to support effective and safe pharmacotherapy: Pediatrics as an example.	Dr. Tjitske van der Zanden
11 A review on the role of extrapolation as basis for paediatric marketing authorisation applications of medicines in the EU.	Loes Maton
12 Preventing life-threatening symptoms of Noonan syndrome: Is it feasible to treat intra-uterine with trametinib?	Emmely Wagener
13 On-Label Paediatric Drug Product Information in Switzerland – the Neglected Child	Lukas Higi
14 Evaluation of nine population pharmacokinetic models for model-based vancomycin concentration monitoring in a local population of neonates	Verena Gotta
15 MEDeHelp – development of an emergency mobile application for Europe	Karin Kaeser
16 Paracetamol concentrations and time-course of ductus arteriosus diameter in extreme preterm neonates: a population pharmacokinetic-pharmacodynamic analysis	Faheemah Padavia
17 The REPAIR-NEO study protocol to test a workflow on drug development in neonates undergoing therapeutic hypothermia.	Prof. dr. Karel Allegaert
18 Quantifying milk and maternal postpartum changes to improve drug safety in breastfeeding	PhD Neel Deferm
19 Developing evidence-based dosing recommendations for intravenous ciprofloxacin in critically ill children: a population pharmacokinetic study using total and unbound concentrations	PhD Pieter-Jan De Sutter
20 In vivo cytochrome P450 1A2 activity in adolescents with and without obesity	MD, Associate Professor Christina Gade
21 Assessing the predictive performance of a population pharmacokinetic model for paracetamol and its metabolites in an external dataset of neonates, infants, and children receiving paracetamol as analgesic after cardiac surgery.	Vita Melton
22 Population pharmacokinetics of morphine in children under 3 years after cardiothoracic surgery: External validation and extrapolation of published models	Maria Xiberras
23 Use of virtual populations to investigate 'weekend-off' efavirenz dosing in adults and adolescents with different CYP2B6 526 G>T genotypes	Dr. Lisa Almond
24 optimizing high-dose methotrexate dosing for the treatment of infant acute lymphoblastic leukemia	MSc Tirsa de Kluis
25 Establishing evidence-based, model-informed dose recommendations for amoxicillin in pregnancy	Dagmar Hiensch
26 Optimizing paediatric opioid conversion and methadone tapering: physiologically-based pharmacokinetic modelling in critically ill children	MSc Marika de Hoop
27 Physiologically Based Pharmacokinetic Modeling of Ivacaftor/Tezacaftor/Elexacaftor in Children with Cystic Fibrosis: Evaluating Hepatic and Intestinal CYP3A4 Ontogeny	Femke Elzinga
28 Evidence-based dose recommendations for preterm and term neonates: the neodose project	Lianne van Bussel
29 Optimization of microdialysis experiments to study antibiotic disposition in children: lessons learnt	Ir. Isis Van herteryck
30 Weight-based dosing of monoclonal antibodies in paediatrics: a systematic study of population pharmacokinetics studies to evaluate its impact on exposure of infliximab across the paediatric age range	Tine Mirchi
31 Plasma protein binding: can we use piglets to study unbound drug disposition in children?	Ir. Isis Van herteryck
32 Osmolality of oral liquid medications intended for neonates and infants: a laboratory-based study	Dotan Shaniv
33 Hyperosmolar preparations and necrotizing enterocolitis: can a single overdose tip the balance? a case report	Dotan Shaniv
34 Ontogeny of hepatic and intestinal CYP3A activity across the pediatric age range quantified using population Physiologically-Based Pharmacokinetic modelling	Aymara Sancho Araiz
35 Drug utilisation at a German neonatal intensive care unit – Are evidence-based (off-label) dosing recommendations available?	Dr. Sonja Eberl
36 Coproporphyrin I as biomarker in a pediatric population: Age-related differences and genetic influences	Leila Potzel
37 Extravasation of Vesicant and Irritant Drugs in Pediatric Patients-A Literature Review	Dr. med. Christiane Garnemark
38 The reality of prescribing selected medications in the pediatric population: a single centre experience.	Pavla Pokorna
39 Personalized Immunomodulatory Drug Repurposing in Patients with Mucopolysaccharidosis	Anna-Maria Wiesinger
40 "Meet the Pain" is an educational multidisciplinary project to improve the pain assessment skills of neonatal intensive care unit nurses	MD Hana Jancova
41 To re-dose or not? A decision-making flowchart after vomiting in the paediatric population	Sahar Alozai
42 Causality, Severity and Avoidability of Adverse Drug Reactions in Children over an 11-year period	Dr. Duaa Gaafar
43 Trends in paediatric hypnotic prescriptions in France, 2016-2023	Zaba Valtuille
44 Patterns of paediatric methylphenidate users: a national time series analysis from 2016 to 2023	Zaba Valtuille
45 Model-based blood pressure prediction for personalized medicine for people at any age	Sabina Schlottau
46 Maternal drug use and infant exposure during breastfeeding	Ditte Resendal
47 Effect of SARS-CoV-2 on psychotropic drug use in children: a population-based longitudinal study	Mag.pharm. Dr. Hans-Jürgen Gober
48 Predictive performance, and model refinement, of physiologically based pharmacokinetic (PBPK) models for CYP3A inhibitors clarithromycin and fluconazole in a virtual paediatric population	Roz Southall
49 Integrated, multimodal collaboration to support paediatric pharmacology and drug development: the conect4children (c4c) project and c4c stichting	Fenna Mahler
50 Comparison of maternal and fetal exposure to escitalopram, sertraline, and paroxetine during pregnancy combining human ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling	Gabrielle LUI
51 Comparative analysis of breast milk and infant formulas: microbiome and health implications	PhD candidate David Rojas-Velazquez
52 Sedative antipsychotic use by children and adolescents in the Netherlands: Dosages, duration and prescribers	Ir. Ravish Gangapersad
53 Impact of Discontinuing Open-Label Doxapram use in Neonates on Informed Consent Rates in the DOXA-Trial	Kelly Storm
54 The CANDi project's first step: prioritization of off-label drug-indications warranting further assessment.	Dr. Violette Gijsen
55 Trends in hospitalizations for accidental poisoning in children in France, 2016-2023	Zaba Valtuille
56 Estimated glomerular filtration rates in neonates undergoing therapeutic hypothermia	Prof. dr. Karel Allegaert
57 Use of medication for gastroesophageal reflux during pregnancy and adverse birth outcomes	Dr. Marleen van Gelder